Company intelligence / Profile preview

Circe Bioscience

Boston, Massachusetts, United Statesmadelinemiller.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Circe Bioscience has developed a proprietary gas fermentation process that uses engineered microbes to convert carbon dioxide, water, and electricity into high-value organic molecules. Their process removes 3 kg of CO₂ per 1 kg of product. The initial focus includes producing food-grade fats like cocoa butter as well as biodegradable plastics, with broader applications across chemicals and fuels. The technology spun out from Harvard’s Wyss Institute in 2021 and has received significant funding including $3.2M from ARPA-E ECOSynBio.

Modalities: Fermentation-based production platform (using engineered microbes)
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Circe Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Circe Bioscience.

Explore the full profile